https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic?utm_source=sfmc&utm_medium=email&utm_campaign=ASH+Practice+Update+-+December+2023&utm_term=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic&utm_id=298317&sfmc_id=20123841
On December 1, 2023, the Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with chronic...
chronic lymphocytic leukemiaaccelerated approvalfdagrantspirtobrutinib
https://www.ajmc.com/view/most-patients-with-mcl-in-study-of-pirtobrutinib-show-stable-or-improved-physical-symptoms-qol
Patients with mantle cell lymphoma experience improved quality of life and physical functioning after treatment with pirtobrutinib, a BTK inhibitor.
patientsmclstudypirtobrutinibshow